Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

13.30 0.51 −3.69%
Market cap
$1.2B
P/E
16.4×
Fwd P/E
21.4×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
11.65 21.23 21.88 55.75

+8 more quarters

P/S ratio
1.10 1.07 0.87 0.79
P/FCF ratio
6.80 6.11 6.87 8.37
P/Operating CF
32.24 68.77 13.06 14.88
P/B ratio
2.31 2.62 2.17 2.16
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
1.48 1.48 1.30 1.29
EV/EBITDA
8.30 8.19 7.31 8.10
EV/Operating CF
8.87 8.26 9.89 13.00
EV/FCF
9.12 8.45 10.24 13.62
Quick Ratio
1.10 1.06 1.12 1.07
Current Ratio
1.69 1.69 1.70 1.74
Net Debt/EBITDA
7.28 12.04 7.78 12.38
Debt/Assets
36.90% 41.82% 43.00% 45.98%
Debt/Equity
0.90 1.16 1.29 1.56
Asset Turnover
0.84 0.86 0.80 0.77
Operating CF/Net income
0.59 2.87 2.57 9.54
Capex/Depreciation
(0.09) (0.05) (0.05) (0.04)
Interest Coverage
4.70 1.95 3.67 1.82
Research and Development Expense of Revenue
2.07% 1.87% 1.90% 2.11%
Selling, General and Administrative Expense of Revenue
54.01% 59.30% 52.41% 56.73%
Intangible Assets out of Total Assets
0.53 0.56 0.55 0.55
Share Based Compensation of Revenue
3.29% 2.47% 2.18% 2.29%
Graham Net Nets
(0.22) (0.27) (0.37) (0.48)
Graham Number
8.63 5.80 5.12 2.89
Earnings Yield
8.58% 4.71% 4.57% 1.79%
Free Cash Flow Yield
14.72% 16.38% 14.55% 11.94%
Revenue per Share
2.26 1.96 2.37 2.07
Operating CF per Share
0.29 0.13 0.57 0.45
Capex per Share
(0.01) (0.01) (0.01) (0.01)
Free Cash Flow per Share
0.28 0.12 0.56 0.44
Cash per Share
0.43 0.53 0.77 0.63
Shareholders Equity per Share
4.09 3.48 3.43 3.10
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.09 3.48 3.43 3.10
Free Cash Flow
18.91 8.36 37.39 29.63
Working Capital
105.08 101.72 112.46 119.15
Capital Expenditures
(0.96) (0.57) (0.58) (0.47)
Net Current Asset Value
(138.41) (166.46) (182.27) (213.44)
EV/EBIT
14.75 14.79 13.68 17.26
Capex to Sales
0.01 0.00 0.00 0.00
Price to Operating Income
10.99 10.68 9.18 10.61
Other line items
Average Receivables
135.39 119.30 127.85 126.16
Average Payables
22.22 21.62 17.31 21.75
Average Inventory
88.14 88.62 87.36 93.15
Average Assets
690.07 670.98 705.76 735.54
Average Common Equity
239.36 209.87 207.03 197.04

Fold the line items

Columns are period end dates